Jeremy Payne, MD
Neurology · Flagstaff, AZNPI 1699727784
Payments from drug & device makers
Across 52 payments — averaging $293.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$14K
- AstraZeneca$149
- Amgen$114
- AbbVie$106
- Novartis$87
- Genentech USA, Inc.$51
- plus $349 from 11 others
What the payments were for
- Consulting fees$3002%
- Speaking & faculty fees$13,67590%
- Food & beverage$1,2908%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 16 | $14,409 |
| AstraZeneca(2 entities) | 4 | $149 |
| Amgen | 2 | $114 |
| AbbVie(2 entities) | 6 | $106 |
| Novartis | 5 | $87 |
| Genentech USA, Inc. | 2 | $51 |
| Eisai Inc. | 3 | $51 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $46 |
| Penumbra, Inc. | 1 | $40 |
| Abbott | 1 | $39 |
| Biosense Webster, Inc. | 2 | $35 |
| Dexcom, Inc. | 1 | $30 |
| Greenwich Biosciences, Inc. | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Promius Pharma LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$14,085
- EMBOTRAP II Revascularization Device$140
How this compares
$15,265 in reported general payments places this provider in the 60th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 20 | $1,708 |
| Levetiracetam | 40 | $1,473 |
| Gabapentin | 27 | $567 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 24 | $320 |
| Azathioprine | 12 | $262 |
| Memantine Hcl | 12 | $258 |
| Donepezil Hcl | 13 | $215 |
| Sumatriptan Succinate | 12 | $172 |
| Primidone | 12 | $146 |
| Atorvastatin Calcium | 11 | $124 |
| Prednisone | 11 | $10 |
Paid to pharmacies, not to this prescriber.
Other neurology in Flagstaff
- David WeidmanPhoenix$7.4M
- Hemant PandeyChandler$6.2M
- Stephen FlitmanPhoenix$4.4M
- Barry HendinPhoenix$4.4M
- Jeremy ShefnerPhoenix$3M
- Danielle CabralPhoenix$2.8M
- Suraj MuleyPhoenix$2.8M
- Todd SchwedtPhoenix$2.8M
- Todd LevinePhoenix$2.7M
- Nida LaurinScottsdale$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.